Refine by
Tissue Biopsy Articles & Analysis
21 news found
DR CHENG BOON, ONCOLOGIST IN THE PRIVATE SECTOR AND THE NHS AS WELL AS ACTING AS ONCODNA UK MEDIAL DIRECTOR COMMENTED: “In my view, this is an important first step in a collaboration that will make it much easier for public and privately practising oncologists to access biopsy tissue and request ONCODEEP* for the purpose of routine next generation ...
Northstar Response is a methylation-based, tissue-agnostic treatment response monitoring assay. Using our molecular counting technology, the assay provides absolute quantification of methylated circulating tumor DNA (ctDNA) burden. ...
(Nasdaq: GH), a leading precision oncology company, and the Vall d’Hebron Institute of Oncology (VHIO), one of Europe’s leading cancer research organizations, today announced that the first blood-based cancer testing services in Europe based on Guardant Health’s industry-leading digital sequencing platform are now available at the VHIO liquid biopsy testing ...
Organoids are stem cell-derived mini-organs developed from any patient resection or biopsy tissue that can be grown in the laboratory, which can be applied like conventional cell lines in early drug discovery. ...
The new sheath, the company says, makes the system the “first and only” integrated biopsy device not requiring the use of additional instruments. "The FDA approval of our LUMINELLE Bx Sheath not only marks a major milestone for UVision360, but is also a game changer when it comes to the standard of care for tissue biopsy ...
Feeney’s expertise building sales and market access teams across specialty areas, including liquid biopsy, oncology, and women's health, will play a critical role in advancing the commercial strategy and development of 4D Path’s cancer diagnostic and precision oncology platform technology. ...
The test integrates genomic and epigenomic signatures to detect disease without the need for tumor tissue. (Abstract 168) Additionally, clinical utility data will demonstrate that the Guardant360® liquid biopsy test detects microsatellite instability-high (MSI-H) status in patients with advanced gastrointestinal cancers at a similar frequency to ...
Cleared by the FDA, VelacurTM is a handheld, point of care ultrasound solution that quantifies liver stiffness using technology similar to MRI elastography combined with 3D tissue sampling. Unlike biopsy and MRI, the procedure is non-invasive, comfortable and convenient. ...
THE TWO BELGIAN COMPANIES WILL WORK TOWARDS A BETTER UNDERSTANDING OF NON-SMALL CELL LUNG CANCER BIOLOGY AND CHARACTERIZATION OF THE TUMORS USING AI TECHNOLOGY Radiomics and OncoDNA are pleased to announce that they have entered into a strategic agreement, combining Radiomics’ next-generation AI-based technology to extract quantitative information embedded in medical images with ...
SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, has entered into an assay development agreement with the global, science-led biopharmaceutical company AstraZeneca (LSE/STO/Nasdaq: AZN). SAGA Diagnostics will in the course of this agreement develop unique ...
The LUMINELLE DTx System is an endoscopic platform assisting both male/female procedures, bringing operating room capabilities affordably to physician offices so bladder and uterine tissue samples can be obtained easily with visualization. "The FDA approval of our LUMINELLE Bx Sheath not only marks a major milestone for UVision360 but is also a game changer when it comes to the ...
SAGA Diagnostics AB (“SAGA”), a cancer liquid biopsy and genomic testing company, today announced that it has raised SEK 106 million (€10.5 million) in a Series A2 financing from both existing and new investors. ...
“Understanding a patient’s gene expression within atherosclerotic plaque may provide novel prognostic insights. This typically would require tissue biopsy or surgery, which is not feasible for most patients,” said Dr. ...
ByElucid
This review paper provides unique insight into liquid biopsies and the field of exosomes in the context of other liquid biopsies such as cfDNA and CTC analysis. ...
CrossBay Medical receives FDA Clearance for CrossGlide™ ETS Plus for frictionless, office-based endometrial biopsy procedures focused on patient comfort. Similar to the CrossGlide ETS, Endometrial Tissue Sampler (which received FDA clearance this summer), the ETS Plus also enables medical providers to perform a frictionless, office-based endometrial ...
The Oncomine Precision Assay, which is designed to detect key biomarkers from formalin-fixed paraffin-embedded (FFPE) tissue and liquid biopsy specimens, contains more than 50 cancer-related biomarkers and has the lowest sample input requirements on the market for detection of both DNA and RNA variants. ...
The Oncomine Precision Assay can detect more than 50 cancer-related biomarkers from formalin-fixed paraffin-embedded (FFPE) tumor tissues or liquid biopsy specimens. It is designed to run on the Genexus System, a first-of-its-kind NGS platform that features an automated workflow with a one-day turnaround time and the lowest sample requirements on the market for ...
The Oncomine Precision Assay is a next-generation sequencing (NGS) assay that is used to detect key biomarkers from formalin-fixed paraffin-embedded (FFPE) tissue or liquid biopsy specimen. The assay contains more than 50 cancer-related biomarkers and, when run on the Genexus System, features an automated workflow with a one-day turnaround time and the lowest ...
Coughed-up sputum and invasive biopsies that do not work well in critical patient cohorts and blood culture tests which take weeks to get results are limiting factors and can give many false negatives”. ...
AVRA will utilize oVio’s imaging technology to “robotize” a wide range of medical procedures that are currently being performed by human hands, such as: biopsies, tissue targeting, neurological repair, internal organ procedures and more. ...